↑ 薬物リストへ　← 戻る

Mifepristone    (DrugBank: Mifepristone)

1 disease
告示番号疾患名（ページ内リンク）臨床試験数
75クッシング病10

75. クッシング病　［臨床試験数：191，薬物数：172（DrugBank：48），標的遺伝子数：61，標的パスウェイ数：121］
Searched query = "Cushing disease", "Cushing"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
10 / 191 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT01925092
(ClinicalTrials.gov)		August 20138/8/2013Mifepristone in Children With Refractory Cushing's DiseaseAn Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of Mifepristone in Children With Refractory Cushing's DiseaseCushing's DiseaseDrug: mifepristoneCorcept TherapeuticsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Withdrawn6 Years17 YearsBoth0Phase 3United States
2NCT01371565
(ClinicalTrials.gov)		November 20107/6/2011Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's SyndromeCompassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's SyndromeCushing's Disease;Cushing's SyndromeDrug: MifepristoneCorcept TherapeuticsNULLCompleted18 YearsN/AAll4Phase 3United States
3NCT00936741
(ClinicalTrials.gov)		July 20099/7/2009An Extension Study of CORLUX in the Treatment of Endogenous Cushing's SyndromeAn Open Label Extension Study of the Efficacy and Safety of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's SyndromeCushing's SyndromeDrug: mifepristoneCorcept TherapeuticsNULLCompleted18 YearsN/AAll30Phase 3United States
4NCT00721201
(ClinicalTrials.gov)		November 200821/7/2008Glucocorticoid Receptor Antagonism in Subclinical CushingsA Pilot Study of the Effect of a Glucocorticoid Receptor Antagonist in Patients With Subclinical CushingsSubclinical Cushing'sDrug: MifepristoneSheffield Teaching Hospitals NHS Foundation TrustNULLCompleted18 YearsN/ABoth6Phase 1;Phase 2United Kingdom
5NCT00569582
(ClinicalTrials.gov)		December 20075/12/2007A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's SyndromeAn Open-label Study of the Efficacy and Safety of CORLUX (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's SyndromeCushing's SyndromeDrug: mifepristoneCorcept TherapeuticsNULLCompleted18 YearsN/AAll50Phase 3United States
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
6NCT00422201
(ClinicalTrials.gov)		May 15, 200712/1/2007Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) SecretionProspective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) SecretionCushing's SyndromeDrug: MifepristoneHRA PharmaNULLTerminated18 Years85 YearsAll18Phase 2United States;France;Germany;Italy;Netherlands;United Kingdom
7EUCTR2006-004679-36-DE
(EUCTR)		05/04/200709/10/2006Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. - HRA052015 in EASProspective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. - HRA052015 in EAS Treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion.
MedDRA version: 14.0;Level: PT;Classification code 10011652;Term: Cushing's syndrome;System Organ Class: 10014698 - Endocrine disorders
MedDRA version: 14.0;Classification code 10014146;Term: Ectopic ACTH syndrome;System Organ Class: 10014698 - Endocrine disorders;Therapeutic area: Diseases [C] - Hormonal diseases [C19]		Product Code: HRA052015
INN or Proposed INN: mifepristone
Other descriptive name: 17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one		Laboratoire HRA PharmaNULLNot RecruitingFemale: yes
Male: yes		35France;United States;Netherlands;Germany;Italy
8EUCTR2006-004679-36-NL
(EUCTR)		22/03/200731/01/2007Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. - HRA052015 in EASProspective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. - HRA052015 in EAS Treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion.
MedDRA version: 8.1;Level: LLT;Classification code 10014155;Term: Ectopic corticotrophin syndrome		Product Code: HRA052015
INN or Proposed INN: mifepristone
Other descriptive name: 17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one		Laboratoire HRA PharmaNULLNot RecruitingFemale: yes
Male: yes		22Germany;Netherlands;France;Italy
9EUCTR2006-004679-36-IT
(EUCTR)		15/01/200730/01/2007Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing s syndrome caused by ectopic Adrenal Corticotrophin Hormone ACTH secretion - HRA052015 in EASProspective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing s syndrome caused by ectopic Adrenal Corticotrophin Hormone ACTH secretion - HRA052015 in EAS Cushing s Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone ACTH Secretion
MedDRA version: 9.1;Level: LLT;Classification code 10014146;Term: Ectopic ACTH syndrome		Product Name: Mifepristone
Product Code: HRA052015		LABORATOIRE HRA PHARMANULLNot RecruitingFemale: yes
Male: yes		22Germany;Netherlands;France;Italy
10EUCTR2006-004679-36-FR
(EUCTR)		13/12/200629/09/2006Prospective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. - HRA052015 in EASProspective, open-label, multicenter, international study of mifepristone for symptomatic treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion. - HRA052015 in EAS Treatment of Cushing's syndrome caused by ectopic Adrenal Corticotrophin Hormone (ACTH) secretion.
MedDRA version: 8.1;Level: LLT;Classification code 10014155;Term: Ectopic corticotrophin syndrome		Product Code: HRA052015
INN or Proposed INN: mifepristone
Other descriptive name: 17ß-hydroxy-11ß-(4-dimethylaminophenyl)17a-(prop-1-ynyl)estra-4,9-dien-3-one		Laboratoire HRA PharmaNULLNot RecruitingFemale: yes
Male: yes		22France;Netherlands;Germany;Italy

先頭へ